transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologiststransplantologiya-13Research ArticleАКТУАЛЬНЫЕ ВОПРОСЫ ТРАНСПЛАНТОЛОГИИACTUAL ISSUES OF TRANSPLANTATIONДлительное применение эверолимуса в качестве одного из компонентов иммуносупрессивной терапии у реципиентов печениLong-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipientsМ.Ш. Хубутия,М. Ш.KhubutiaM. ShСюткинВ. Е.SjutkinV. E.КузнецоваН. К.KuznetsovaN. K.ЖуравельС. В.ZhuravelS. V.sjuravel@rambler.ruНоврузбековМ. С.NovruzbekovM. S.ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗ Москвы»РоссияSklifosovsky Research Institute for Emergency Medicine, MoscowRussian Federation20132601201602Трансплантология2327Copyright © М.Ш. Хубутия, М.Ш., Сюткин В.Е., Кузнецова Н.К., Журавель С.В., Новрузбеков М.С., 20162016М.Ш. Хубутия, М.Ш., Сюткин В.Е., Кузнецова Н.К., Журавель С.В., Новрузбеков М.С.Khubutia M.S., Sjutkin V.E., Kuznetsova N.K., Zhuravel S.V., Novruzbekov M.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/13

В статье освещен трехлетний опыт использования ингибиторов mTOR в схемах иммуносупрессивной терапии у пациентов после трансплантации печени.

This article presents a three-year experience with mTOR inhibitors in the schemes of immunosuppressive therapy in patients post liver transplantation.

трансплантация печенииммуносупрессивная терапияингибиторы mTORliver transplantationimmunosuppressive therapyinhibitors mTORReferencesCalcineurin inhibitor minimization protocols in liver transplantation / S.A. Farkas [et al.] // Transpl Int. – 2009. – Vol. 22. – N1. – P. 49–60.Calcineurin inhibitor minimization protocols in liver transplantation / S.A. Farkas [et al.] // Transpl Int. – 2009. – Vol. 22. – N1. – P. 49–60.Fung, J. Rapamycin: friend, foe, or misunderstood? / J. Fung, A. Marcos // Liver Transpl. – 2003. – Vol. 9. – N5. – P. 469–472.Fung, J. Rapamycin: friend, foe, or misunderstood? / J. Fung, A. Marcos // Liver Transpl. – 2003. – Vol. 9. – N5. – P. 469–472.A Decade of Experience Using mTor Inhibitors in Liver Transplantation / J. Campsen [et al.] // J Transplant. – 2011. – doi: 10.1155/2011/913094.A Decade of Experience Using mTor Inhibitors in Liver Transplantation / J. Campsen [et al.] // J Transplant. – 2011. – doi: 10.1155/2011/913094.Chronic renal failure after transplantation of a nonrenal organ / A.O. Ojo [et al.] // N Engl J Med. – 2003. – Vol. 349. – N 10. – P. 931–940.Chronic renal failure after transplantation of a nonrenal organ / A.O. Ojo [et al.] // N Engl J Med. – 2003. – Vol. 349. – N 10. – P. 931–940.Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study / S. Karie-Guigues [et al.] // Liver Transpl. – 2009. – Vol. 15. – N9. – P. 1083–1091.Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study / S. Karie-Guigues [et al.] // Liver Transpl. – 2009. – Vol. 15. – N9. – P. 1083–1091.Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function / P. De Simone [et al.] // Transpl Int. – 2009. – Vol. 22. – N 3. – P. 279–286.Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function / P. De Simone [et al.] // Transpl Int. – 2009. – Vol. 22. – N 3. – P. 279–286.Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation / J.M. Martinez et al. // Transplant Proc. – 2010. – P. 42. – N 2. – P. 641–643.Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation / J.M. Martinez et al. // Transplant Proc. – 2010. – P. 42. – N 2. – P. 641–643.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial / M.F. Abdelmalek [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 3. Р – 694–705.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial / M.F. Abdelmalek [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 3. Р – 694–705.Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial / P. De Simone [et al.] // Liver Transpl. – 2009. – Vol. 15. – N 10. – P. 1262–1269.Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial / P. De Simone [et al.] // Liver Transpl. – 2009. – Vol. 15. – N 10. – P. 1262–1269.Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function / M. Masetti [et al.] // Am J Transplant. – 2010. – Vol. 10. – N 10. – P. 2252–2262.Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function / M. Masetti [et al.] // Am J Transplant. – 2010. – Vol. 10. – N 10. – P. 2252–2262.Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial / P. De Simone [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 11. – P. 3008–3020.Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial / P. De Simone [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 11. – P. 3008–3020.A randomized, controlled study to assess the conversion from calcineurininhibitors to everolimus after liver transplantationPROTECT / L. Fischer [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 7. – P. 1855–1865.A randomized, controlled study to assess the conversion from calcineurininhibitors to everolimus after liver transplantationPROTECT / L. Fischer [et al.] // Am J Transplant. – 2012. – Vol. 12. – N 7. – P. 1855–1865.Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results / G. Levy [et al.] // Liver Transpl. – 2006. – Vol. 12. – N 11. – P. 1640–1648.Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results / G. Levy [et al.] // Liver Transpl. – 2006. – Vol. 12. – N 11. – P. 1640–1648.Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis / F. Saliba [et al.] // Liver Transpl. – 2011. – Vol. 17. – N 8. – P. 905–913.Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis / F. Saliba [et al.] // Liver Transpl. – 2011. – Vol. 17. – N 8. – P. 905–913.

The authors declare that there are no conflicts of interest present.